| Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition J Ren, X Liu, C Fang, S Jiang, CH June, Y Zhao Clinical cancer research 23 (9), 2255-2266, 2017 | 915 | 2017 |
| Generation of pig induced pluripotent stem cells with a drug-inducible system Z Wu, J Chen, J Ren, L Bao, J Liao, C Cui, L Rao, H Li, Y Gu, H Dai, ... Journal of molecular cell biology 1 (1), 46-54, 2009 | 529 | 2009 |
| Generation of induced pluripotent stem cell lines from adult rat cells J Liao, C Cui, S Chen, J Ren, J Chen, Y Gao, H Li, N Jia, L Cheng, H Xiao, ... Cell stem cell 4 (1), 11-15, 2009 | 498 | 2009 |
| A versatile system for rapid multiplex genome-edited CAR T cell generation J Ren, X Zhang, X Liu, C Fang, S Jiang, CH June, Y Zhao Oncotarget 8 (10), 17002, 2017 | 408 | 2017 |
| Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18 B Hu, J Ren, Y Luo, B Keith, RM Young, J Scholler, Y Zhao, CH June Cell reports 20 (13), 3025-3033, 2017 | 380 | 2017 |
| Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells Y Lin, Y Yang, W Li, Q Chen, J Li, X Pan, L Zhou, C Liu, C Chen, J He, ... Molecular cell 48 (4), 627-640, 2012 | 175 | 2012 |
| Reprogramming of ovine adult fibroblasts to pluripotency via drug-inducible expression of defined factors L Bao, L He, J Chen, Z Wu, J Liao, L Rao, J Ren, H Li, H Zhu, L Qian, ... Cell research 21 (4), 600-608, 2011 | 165 | 2011 |
| CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia Y Hu, Y Zhou, M Zhang, W Ge, Y Li, L Yang, G Wei, L Han, H Wang, S Yu, ... Clinical Cancer Research 27 (10), 2764-2772, 2021 | 156 | 2021 |
| Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9 J Ren, Y Zhao Protein & cell 8 (9), 634-643, 2017 | 124 | 2017 |
| Generation of hircine-induced pluripotent stem cells by somatic cell reprogramming J Ren, Y Pak, L He, L Qian, Y Gu, H Li, L Rao, J Liao, C Cui, X Xu, J Zhou, ... Cell research 21 (5), 849-853, 2011 | 81 | 2011 |
| Generating hypoimmunogenic human embryonic stem cells by the disruption of beta 2-microglobulin P Lu, J Chen, L He, J Ren, H Chen, L Rao, Q Zhuang, H Li, L Li, L Bao, ... Stem Cell Reviews and Reports 9, 806-813, 2013 | 75 | 2013 |
| Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study Y Hu, Y Zhou, M Zhang, H Zhao, G Wei, W Ge, Q Cui, Q Mu, G Chen, ... Cell research 32 (11), 995-1007, 2022 | 62 | 2022 |
| Highly efficient derivation of skeletal myotubes from human embryonic stem cells L Rao, W Tang, Y Wei, L Bao, J Chen, H Chen, L He, P Lu, J Ren, L Wu, ... Stem Cell Reviews and Reports 8, 1109-1119, 2012 | 41 | 2012 |
| Altering gene expression in cart cells and uses thereof Y Zhao, REN Jiangtao, X Liu, CH June | 18 | 2018 |
| Multiplex Cripsr/Cas9 genome editing to generate potent universal CART and PD1-deficient cells against leukemia J Ren, X Liu, C Fang, S Jiang, CH June, Y Zhao Blood 126 (23), 4280, 2015 | 17 | 2015 |
| Genetic editing and interrogation with Cpf1 and caged truncated pre-tRNA-like crRNA in mammalian cells X Zhang, L Xu, R Fan, Q Gao, Y Song, X Lyu, J Ren, Y Song Cell Discovery 4 (1), 36, 2018 | 16 | 2018 |
| Altering gene expression in modified T cells and uses thereof Y Zhao, REN Jiangtao, X Liu, CH June | 15 | 2016 |
| The safety and efficacy of a CRISPR/Cas9-engineered universal CAR-T cell product (CTA101) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia Y Hu, Y Zhou, M Zhang, W Ge, Y Li, L Yang, G Wei, L Han, H Wang, ... Blood 136, 52, 2020 | 8 | 2020 |
| A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma X Zhang, Y Zhou, J Yang, J Li, L Qiu, W Ge, B Pei, J Chen, L Han, J Ren, ... Blood 140 (Supplement 1), 4566-4567, 2022 | 7 | 2022 |
| Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T … Y Liu, Y Zheng, T Deng, Y Huang, Z Liu, B Zhan, X Zhou, R Yan, J Ren, ... Frontiers in Oncology 12, 1037934, 2022 | 7 | 2022 |
Lingjun RaoDuke UniversityVerified email at duke.edu
Lingjun RaoDuke UniversityVerified email at duke.edu